2026 年第 2 期 第 21 卷

莫西沙星与奥玛环素治疗成人支原体肺炎的效果及安全性比较

Comparative efficacy and safety of moxifloxacin versus omadacycline in the treatment of adult Mycoplasma pneumoniae pneumonia

作者：刘岩岩1薛天娇1张媛媛2汤艳芬1王宇1

英文作者：Liu Yanyan1 Xue Tianjiao1 Zhang Yuanyuan2 Tang Yanfen1 Wang Yu1

单位：1首都医科大学附属北京地坛医院呼吸科，北京100015；2首都医科大学附属北京地坛医院传染病溯源预警与智能决策全国重点实验室，北京100015

英文单位：1Department of Respiratory Beijing Ditan Hospital Capital Medical University Beijing 100015 China; 2National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases Beijing Ditan Hospital Capital Medical University Beijing 100015 China

关键词：肺炎支原体肺炎；莫西沙星；奥玛环素；安全性

英文关键词：Mycoplasmapneumoniaepneumonia;Moxifloxacin;Omadacycline;Safety

• 摘要：

• 目的 比较莫西沙星与奥玛环素对成人肺炎支原体肺炎（MPP）的效果及安全性。方法 回顾性收集2024年8—12月首都医科大学附属北京地坛医院收治的139例成人MPP患者的临床资料，其中接受奥玛环素治疗73例（观察组）、接受莫西沙星治疗66例（对照组）。分析2组临床指标、退热时间、症状缓解率、临床指标、肺部影像改善情况及安全性。结果 治疗后，2组白细胞计数、中性粒细胞/淋巴细胞比值、C反应蛋白、降钙素原、血清淀粉样蛋白A、白细胞介素6水平均优于治疗前（均P＜0.05），但2组间比较差异均无统计学意义（均P＞0.05）。观察组退热时间短于对照组［（1.3±0.5）d比（2.1±0.8）d］（P＝0.02）。观察组与对照组总有效率比较差异无统计学意义［91.8%（67/73）比90.9%（60/66）］（P＝0.85）。治疗1、4周后，2组影像学吸收比例比较差异均无统计学意义（均P＞0.05）。治疗期间，观察组不良反应发生率低于对照组［2.7%（2/73）比12.1%（8/66）］（χ2＝7.93，P＜0.01）。结论 奥玛环素与莫西沙星在成人MPP治疗方面效果无差异，且具有安全性方面的优势。

• Objective To compare the efficacy and safety of moxifloxacin and omadacycline in the treatment of adult Mycoplasma pneumoniae pneumonia (MPP). Methods The clinical data of 139 adult MPP patients admitted to Beijing Ditan Hospital, Capital Medical University, from August to December 2024 were retrospectively collected. Among them, 73 cases were treated with omadacycline (observation group) and 66 cases with moxifloxacin (control group). The clinical indicators, antipyretic time, symptom remission rate, improvement of pulmonary imaging and safety of the two groups were analyzed. Results After treatment, the levels of white blood cell count, neutrophil/lymphocyte ratio, C-reactive protein, procalcitonin, serum amyloid A and interleukin-6 in both groups were significantly better than those before treatment (all P<0.05), while there were no statistically significant differences between the two groups (all P>0.05). The antipyretic time in the observation group was shorter than that in the control group ［(1.3±0.5)d vs (2.1±0.8)d］(P=0.02). There was no significant difference in the total effective rate between the observation group and the control group ［91.8%(67/73) vs 90.9%(60/66)］(P=0.85). After 1 and 4 weeks of treatment, there were no significant differences in the imaging absorption rate between the two groups (both P>0.05). During the treatment period, the incidence of adverse reactions in the observation group was lower than that in the control group ［2.7%(2/73) vs 12.1%(8/66)］(χ2=7.93, P<0.01). Conclusion Omadacycline has comparable efficacy to moxifloxacin in the treatment of adult MPP, with the advantage of better safety.